A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Prior treatment

• Has major medical illness or unstable medical condition within 3 months before screening
• Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study

Other illness

• Has a known history of stroke or cerebrovascular disease
• Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
• Has structural brain disease
• Has a history of seizures or epilepsy within 5 years before screening
• Has any other major central nervous system trauma, or infections that affect brain function
• Has a bleeding disorder that is not under adequate control
• Has a history of malignancy occurring within 5 years of screening
• Has liver disease

Lab values

• Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
• Has a risk factor for corrected QT interval (QTc) prolongation

Other

• The main exclusion criteria include but are not limited to the following:
• Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
• Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision

• The main inclusion criteria include but are not limited to the following:
• Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
• Has a designated study partner who can fulfill the requirements of this study
• If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening